The Recall Desk
SevereFDA (Drugs)·D-0321-2022·Announced 2022-01-05

SterRx Norepinephrine 8 mg Sodium Chloride Injection Recalled

SterRx, LLC is recalling 74,508 bags of Norepinephrine 8 mg per 250 mL in 0.9% Sodium Chloride Injection nationwide due to lack of assurance of sterility. The FDA classified this as a Class II recall.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The FDA classified this as a Class II recall involving a sterile injectable drug product with a critical manufacturing defect (lack of sterility assurance). This type of defect in an injectable medication poses serious risk of systemic infection and meets the Severe classification criterion for FDA Class II recalls with significant harm risk.

Plain-English summary

SterRx, LLC is recalling Norepinephrine 8 mg per 250 mL (32 mcg per mL) in 0.9% Sodium Chloride Injection, distributed nationwide. The product is a prescription-only injectable medication. A total of 74,508 bags across multiple lot codes are affected.

The recall is due to lack of assurance of sterility. This means the manufacturer cannot confirm that the affected units meet required sterility standards for injectable medications.

Consumers and healthcare providers who have received or dispensed these products should not use them. Patients currently receiving this medication should consult their healthcare provider immediately. The affected lot codes are identified in the FDA recall notice and span from November 2021 through April 2022.

The recalled product

Product
NOREPINEPHRINE, 8 mg per 250 mL, (32 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-676-01.
Manufacturer
SterRx, LLC
Hazard
  • sterility-failure
  • infection-risk
  • contamination

Distribution

Distributed nationwide across the United States.